Uveitis

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 3, 2006, Pages 487-505

  Muñoz Fernández, Santiago ^a   Martín Mola, Emilio ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

spondyloarthritides; spondyloarthritis; uveitis; uveitis anterior

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ATROPINE; AZATHIOPRINE; BETAMETHASONE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOPLEGIC AGENT; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYDRIATIC AGENT; PHENYLEPHRINE; PLACEBO; PREDNISOLONE; PREDNISONE; RAPAMYCIN; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY;

ACUTE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE EXACERBATION; EYE INFECTION; HUMAN; IRIDOCYCLITIS; MEDICAL SPECIALIST; OPHTHALMOLOGY; PATHOGENESIS; PATIENT CARE; PHYSICAL DISABILITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; RHEUMATOLOGY; SPONDYLOARTHROPATHY; SYSTEMIC DISEASE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL IMPAIRMENT;

ANIMALS; ANTERIOR CHAMBER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; SPONDYLARTHROPATHIES; SULFASALAZINE; UVEITIS;

EID: 33744945268     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.03.008     Document Type: Review

References (49)

1. Bloch-Michel E., and Nussenblatt R.B. International uveitis study group recommendations for the evaluation of intraocular inflammatory disease. American Journal of Ophthalmology 103 (1987) 234-235
2. Gritz D.C., and Wong I.G. Incidence and prevalence of uveitis in Northern California; the Northern California epidemiology of uveitis study. Ophthalmology 111 (2004) 491-500
3. Bodaghi B., Cassoux N., Wechsler B., et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore) 80 (2001) 263-270
4. McCannel C.A., Holland G.N., Helm C.J., et al. Causes of uveitis in the general practice of ophthalmology. UCLA community-based uveitis study group. American Journal of Ophthalmology 121 (1996) 35-46
5. Banares A., Jover J.A., Fernandez-Gutierrez B., et al. Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses. Arthritis and Rheumatism 40 (1997) 358-370
6. Edmunds L., Elswood J., and Calin A. New light on uveitis in ankylosing spondylitis. The Journal of Rheumatology 18 (1991) 50-52
7. Banares A., Hernandez-Garcia C., Fernandez-Gutierrez B., and Jover J.A. Eye involvement in the spondyloarthropathies. Rheumatic Diseases Clinics of North America 24 (1998) 771-784
8. Fernandez-Melon J., Munoz-Fernandez S., Hidalgo V., et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. The Journal of Rheumatology 31 (2004) 524-527
9. Chang J.H., McCluskey P.J., and Wakefield D. Acute anterior uveitis and HLA-B27. Survey of Ophthalmology 50 (2005) 364-388
10. Linssen A., Rothova A., Valkenburg H.A., et al. The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Investigative Ophthalmology and Visual Science 32 (1991) 2568-2578
11. Careless D.J., and Inman R.D. Acute anterior uveitis: clinical and experimental aspects. Seminars in Arthritis and Rheumatism 24 (1995) 432-441
12. Feltkamp T.E. Ophthalmological significance of HLA associated uveitis. Eye 4 (1990) 839-844
13. Hammer R.E., Maika S.E., Richardson J.A., et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27 associated human disorders. Cell 63 (1990) 1099-1112
14. Khare S.D., Luthra H.S., and David C.S. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking β2-microglobulin: a model of human spondyloarthropathies. The Journal of Experimental Medicine 182 (1995) 1153-1158
15. Monowarul Islam S.M., Numaga J., Fujino Y., et al. HLA-DR8 and acute anterior uveitis in ankylosing spondylitis. Arthritis and Rheumatism 38 (1995) 547-550
16. Maksymowych W.P., and Russell A.S. Polymorphism in the LMP2 gene influences the relative risk for acute anterior uveitis in unselected patients with ankylosing spondylitis. Clinical and Investigative Medicine 18 (1995) 42-46
17. Rosenbaum J.T., McDevitt H.O., Guss R.B., and Egbert P.R. Endotoxin-induced uveitis in rats as a model for human disease. Nature 286 (1980) 611-613
18. Baggia S., Lyons J.L., Angell E., et al. A novel model of bacterially induced acute anterior uveitis in rats and the lack of effect from HLA-B27 expression. Journal of Investigative Medicine 45 (1997) 295-301
19. Bañares A., Jover J.A., Fernández-Gutierrez B., et al. Bowel inflammation in anterior uveitis and spondyloarthropathy. The Journal of Rheumatology 22 (1995) 1112-1127
20. Maksymowych W. Etiology and pathogenesis of ankylosing spondylitis. In: Hochberg M.C., Silman A.J., Smolen J.S., Weinblatt M.E., and Weisman M.H. (Eds). Rheumatology. 3rd edn (2003), Mosby, St Louis 1183-1192
21. Rosembaun J.T. An algorithm for the systemic evaluation of patients with uveitis: guidelines for the consultant. Seminars in Arthritis and Rheumatism 19 (1990) 248-257
22. Bonilla G., Muñoz-Fernández S., Hidalgo V., et al. Validate of the efficiency of the application of a diagnostic protocol based on the patterns of presentation of uveitis. Arthritis and Rheumatism 44 supplement (2001) S123 [abstract]
23. Fernández-Melón J., Muñoz-Fernández S., Hidalgo V., et al. Utility of a multidisciplinary unit of uveitis. Annals of the Rheumatic Diseases 61 supplement (2002) 303 [abstract]
24. Dougados M., Berenbaum F., Maetzel A., and Amor B. Prévention des épides d'uvéite antérieure aiguë des spondylarthropathies par la salazosulfapyridine. Revue du Rhumatisme 60 (1993) 81-83
25. Benitez-del-Castillo J.M., García-Sánchez J., Iradier T., and Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 14 (2000) 340-343
26. Munoz-Fernandez S., Hidalgo V., Fernandez-Melon J., et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. The Journal of Rheumatology 30 (2003) 1277-1279
27. Braun J., Baraliakos X., Listing J., and Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis and Rheumatism 52 (2005) 2447-2451
28. Becker M.D., Smith J.R., Max R., and Fiehn C. Management of sight-threatening uveitis. New therapeutic options. Drugs 65 (2005) 497-519
29. Jabs D.A., Rosenbaum J.T., Foster C.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. American Journal of Ophthalmology 130 (2000) 492-513
30. BenEzra D., Cohen E., Chajek T., et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplantation Proceedings 20 (1988) 136-143
31. Nussenblatt R.B., de Smet M.D., Rubin B., et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology 115 (1993) 583-591
32. Nussenblatt R.B., Palestine A.G., Chan C.C., et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology 112 (1991) 138-146
33. Nussenblatt R.B., Palestine A.G., and Chan C.C. Cyclosporine therapy for uveitis: long-term followup. Journal of Ocular Pharmacology and Therapeutics 1 (1985) 369-382
34. Vitale A.T., Rodriguez A., and Foster C.S. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology 103 (1996) 365-373
35. de Vries J., Baarsma G.S., Zaal M.J., et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology 74 (1990) 344-349
36. Mathews J.D., Crawford B.A., Bignell J.L., and Mackay I.R. Azathioprine in active chronic iridocyclitis. A double-blind controlled trial. British Journal of Ophthalmology 53 (1969) 327-330
37. Yazici H., Pazarli H., Barnes C.G., et al. controlled trial of azathioprine in Behcet's syndrome. The New England Journal of Medicine 322 (1990) 281-285
38. Samson C.M., Waheed N., Baltatzis S., and Foster C.S. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108 (2001) 1134-1139
39. Mochizuki M., Masuda K., Sakane T., et al. A clinical trial of FK506 in refractory uveitis. American Journal of Ophthalmology 115 (1993) 763-769
40. Shanmuganathan V.A., Casely E.M., Raj D., et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. British Journal of Ophthalmology 89 (2005) 666-669
41. Baltatzis S., Tufail F., Yu E.N., et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110 (2003) 1061-1065
42. Goldstein D.A., Fontanilla F.A., Kaul S., et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 109 (2002) 370-377
43. Nussenblatt R.B., Fortin E., Schiffman R., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 7462-7466
44. Rosenbaum J.T., George R.K., and Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. American Journal of Ophthalmology 127 (1999) 545-549
45. Demiroglu H., Ozcebe O.I., Barista I., et al. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behcet's disease: a randomised trial. Lancet 355 (2000) 605-609
46. Dick A.D., Meyer P., James T., et al. Campath-1H therapy in refractory ocular inflammatory disease. British Journal of Ophthalmology 84 (2000) 107-109
47. Sfikakis P.P., Kaklamanis P.H., Elezoglou A., et al. Infliximab for recurrent, sight-threatening ocular inflammation in adamantiades-behcet disease. Annals of Internal Medicine 140 (2004) 404-406
48. Foster C.S., Tufail F., Waheed N.K., et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Archives of Ophthalmology 121 (2003) 437-440
49. Smith J.A., Thompson D.J., Whitcup S.M., et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Care Research 53 (2005) 18-23